Drug or technology

Cetuximab

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 18, 2026 · PHASE 1/2 TRIAL

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

ClinicalTrials.gov

This is a rollover/access study with no reported efficacy results; it documents continued treatment in benefiting participants and ongoing safety monitoring in Phase 1/2 populations.

PreliminaryTNO155 Advanced Solid Tumors Harboring the KRAS G12C Mutation Cetuximab

Reported

Estimated enrollment40

Primary outcome measure 1Number of participants receiving opnurasib…

Primary outcome measure 2Duration of exposure to study treatment, as…

AUG 6, 2026 · PHASE 1/2 TRIAL

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

ClinicalTrials.gov

This is an active Phase 1/2 trial registration with no results posted; it describes planned enrollment and safety/efficacy endpoints but reports no outcome data.

PreliminaryNCT07286149 Sacituzumab tirumotecan Patritumab deruxtecan

Reported

Planned enrollment140

Primary outcome measure 1Number of Participants Who Experience a Dos…

Primary outcome measure 2Number of Participants Who Experience an Ad…